A phase II trial of human recombinant lnterleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study
Madeline Bauer; Gregory H. Reaman; Jacquelyn A. Hank; Mitchell S. Cairo; Peter Anderson; Bruce R. Blazar; Sharon Frierdich; Paul M. Sondel
- 作者Madeline Bauer; Gregory H. Reaman; Jacquelyn A. Hank; Mitchell S. Cairo; Peter Anderson; Bruce R. Blazar; Sharon Frierdich; Paul M. Sondel
- 卷第75卷
- 期第12期
- 印刷ISSN0008-543X
- 电子ISSN1097-0142
- 文件大小619.42KB
- 发表时间1995
- DOI10.1002/1097-0142(19950615)75:12<2959::aid-cncr2820751225>3.0.co;2-r
- 页码2959-2965